Brought to you by 
Regeneron and Sanofi ride the wave of success; partner again in new cancer antibody deal; Regeneron regains full rights
02 Jun 2022
Executive Summary
Regeneron Pharmaceuticals Inc. and Sanofi continued to build on a very successful relationship by entering into a new drug development deal, this time focusing on PD-1 and other immuno-oncology antibodies over a period of five years (with the possibility of a three-year extension).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Regeneron and Sanofi ride the wave of success; partner again in new cancer antibody deal; Regeneron regains full rights
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice